Titan Technology Makes Bold Move with 55.85 Million Yuan Acquisition of UK Biochemical Firm ASL — What's Behind the Deal?

Shanghai Titan Scientific Co., Ltd. has announced plans to acquire 100% equity in UK-based specialty reagent supplier Apollo Scientific Ltd. (ASL) for approximately  55.85 million yuan (around USD 7.8 million) in cash.

On July 23, Titan signed a share purchase agreement with the current owner of Apollo, Central Glass Co., Ltd., a company listed on the Tokyo Stock Exchange. Upon completion of the transaction, Apollo will become a wholly-owned subsidiary of Titan. Boosted by this news, Titan’s share price rose as much as 6.9% on July 24, closing at 26.95 CNY/share.

Titan stated that the acquisition would enrich its product portfolio by adding a range of innovative chemical products and provide a new overseas production and operational base. The deal is expected to help expand Titan's international sales channels and enhance its global footprint.

Founded in 1993 and based in Manchester, UK, ASL has long served global pharmaceutical companies, biotechnology firms, academic research institutions, and chemical enterprises. It has built an extensive customer base and strong brand influence. Leveraging ASL’s sales network, Titan aims to quickly establish market access in Europe and globally, accelerating its internationalization strategy.

ASL offers a diverse product line, including aromatic, heterocyclic, aliphatic, fluorinated compounds, and life science reagents—boasting a catalog of over 100,000 products and custom synthesis capabilities. Titan has already established itself in the high-end general reagents, analytical equipment, and research consumables sectors, and has a track record of successful acquisitions to strengthen its product line. This acquisition comes at a critical juncture in Titan’s brand evolution and product matrix expansion.

In China, Titan operates a mature supply chain and production facilities capable of producing tens of thousands of tons of high-purity solvents and specialty reagents annually. By combining this with ASL’s inventory and operational systems in the UK and US, the company can establish a two-way procurement channel, enhancing procurement efficiency, reducing costs, and improving the target’s profitability.

Although ASL has been operating at a loss in recent years—with net losses of RMB 6.9 million in 2023 and RMB 5.5 million in 2024—its losses are narrowing, and it is expected to improve further in 2025. Titan believes that with effective integration and synergy, ASL can be turned around and contribute to the acceleration of its global expansion.

Overall, the acquisition reflects Titan Technology’s firm commitment to its internationalization strategy. Through mergers and acquisitions, the company aims to overcome its limitations, optimize its product and sales structure, and strengthen its overseas brand presence. If the integration proceeds smoothly, this overseas acquisition could mark a significant turning point for Titan in the global scientific chemical services sector, potentially unlocking new growth drivers and profit engines for the company.